> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# FDA Grants Zogenix Orphan Status for Lennox Gastaut Drug
- URL: https://www.fdaweb.com/fda-grants-zogenix-orphan-status-for-lennox-gastaut-drug/
- Published: 2017-06-22T12:00:00.000Z
- Updated: 2026-09-14T22:31:00.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5139001

FDA has granted Zogenix an orphan drug designation for its investigational drug, ZX008 (low-dose fenfluramine), for treating Lennox Gastaut Syndrome (LGS), a refractory, debilitating childhood-onset epilepsy. An IND was approved in April for a Phase 3 LGS study involving the drug. Zogenix is currently conducting a Phase 3 program in the U.S. and internationally for ZX008 in Dravet syndrome, another intractable, severe epilepsy that begins in infancy. Top-line data are expected in the third quarter, the company says.